Decoding the emergence of metastatic cancer stem cells

Key points
- In the first study of its kind, Rice University researchers have mapped how information flows through the genetic circuits that cause cancer cells to become metastatic.
- "Cells have genetic circuits that are used to switch certain behaviors on and off," said biophysicist Eshel Ben-Jacob, a senior investigator at Rice's Center for Theoretical Biological Physics and co-author of a new study in the Journal of the Royal Society Interface.
- Metastasis - the spread of cancer between organs - causes more than 90 percent of cancer deaths, but not all tumor cells can metastasize.
- Cancer cells co-opt the EMT process to allow tumor cells to break away and migrate to other parts of the body.
In the first study of its kind, Rice University researchers have mapped how information flows through the genetic circuits that cause cancer cells to become metastatic. The research reveals a common pattern in the decision-making that allows cancer cells to both migrate and form new tumors. Researchers say the commonality may open the door to new drugs that interfere with the genetic switches that cancer must flip to form both cancer stem cells and circulating tumor cells - two of the main players in cancer metastasis.
"Cells have genetic circuits that are used to switch certain behaviors on and off," said biophysicist Eshel Ben-Jacob, a senior investigator at Rice's Center for Theoretical Biological Physics and co-author of a new study in the Journal of the Royal Society Interface. "Though some of the circuits for metastasis have been mapped, this is the first study to examine how cancer uses two of those circuits, in concert, to produce not just cancer stem cells, but also dangerous packs of hybrid stem-like-cells that travel in groups to colonize other parts of the body."
Metastasis - the spread of cancer between organs - causes more than 90 percent of cancer deaths, but not all tumor cells can metastasize. The switch that many cancer cells use to become metastatic is the circuit that governs the epithelial-to-mesenchymal transition, or EMT. The EMT, an important feature in embryonic development and wound healing, allows cells to revert back along their developmental path and take on certain stem-like features that allow them to form new tissues and repair tissue damage.
Cancer cells co-opt the EMT process to allow tumor cells to break away and migrate to other parts of the body. Once there, the cells reverse the switch and transition back to epithelial cells to form a new colony.
In 2013, Ben-Jacob and Rice colleagues José Onuchic, Herbert Levine, Mingyang Lu and Mohit Kumar Jolly discovered that cancer uses the EMT circuitry as a three-way switch. Rather than simply flipping between the epithelial (E) and mesenchymal (M) states, the study showed that cancer had the ability to form E-M hybrids.
In the new study, Ben-Jacob, Levine, Jolly and Lu teamed with Rice graduate student Bin Huang and the University of Texas MD Anderson Cancer Center's Sendurai Mani to examine the interaction between the three-way EMT switch and a second, well-documented genetic switch that gives rise to cancer stem cells (CSCs). The research showed that the CSC circuit also operates as a three-way switch. In addition, the study found "significant correspondence" between the operation of the two switches, which suggests a mechanism that would confer "stemness" on hybrid E-M cancer cells that are known to travel in packs called circulating tumor cells (CTCs).
"According to the prevailing cancer dogma, cells that become fully mesenchymal pose the highest risk of metastasis progression," said Ben-Jacob, adjunct professor of biosciences at Rice. "Indeed, most diagnostic and therapeutic efforts to date have focused on targeting these cells. Notwithstanding that the hybrid cells are more versatile and have the advantage of moving together as a group, they have been assumed to be less harmful than their fully mesenchymal cousins. Our discovery - that squads of hybrid cancer cells also have 'stemness' characteristics - challenges this picture."
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNanotech system, cellular heating may improve treatment of ovarian cancer
The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs,…
18 October 2013
NewsYoung patients with metastatic colorectal cancer are at high risk of disease progression and death
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments. Their disease is more likely to…
28 September 2013
NewsAbiraterone acetate delays quality of life decline in men with metastatic prostate cancer
Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in…






